María Eugenia Alonso Sarasquete-rekin lankidetzan egindako argitalpenak (19)

2022

  1. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

2020

  1. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

2018

  1. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients

    Oncotarget, Vol. 9, Núm. 35, pp. 24081-24096

  2. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  3. Spatio-temporal tumor heterogeneity in metastatic CRC tumors: A mutational-based approach

    Oncotarget, Vol. 9, Núm. 76, pp. 34279-34288

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors

    Oncotarget, Vol. 8, Núm. 64, pp. 107685-107700

2016

  1. Genomic characterization of liver metastases from colorectal cancer patients

    Oncotarget, Vol. 7, Núm. 45, pp. 72908-72922

2015

  1. Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas

    Oncotarget, Vol. 6, Núm. 22, pp. 19070-19086

  2. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

  3. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Altered interphase fluorescence in situ hybridization profiles of chromosomes 4, 8q24, and 9q34 in pancreatic ductal adenocarcinoma are associated with a poorer patient outcome

    Journal of Molecular Diagnostics, Vol. 16, Núm. 6, pp. 648-659

  2. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance

    Haematologica, Vol. 99, Núm. 1, pp. 155-162

2010

  1. Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays

    PLoS ONE, Vol. 5, Núm. 10

2008

  1. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

    British Journal of Haematology, Vol. 141, Núm. 2, pp. 212-215

2007

  1. Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia

    Clinical Lymphoma and Myeloma, Vol. 7, Núm. 9, pp. 573-579

2006

  1. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 135, Núm. 1, pp. 43-51

  2. Microarray-based analysis of spinal versus intracranial meningiomas: Different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression

    Journal of Neuropathology and Experimental Neurology, Vol. 65, Núm. 5, pp. 445-454

2005

  1. Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry

    Haematologica, Vol. 90, Núm. 10, pp. 1365-1372